Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|NnLOCK|S?!LOCK|rChWY%D

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility; Maintaining Our FVE

J&J's revenue grew 6.6% to $25.3 billion in the second quarter, driven by 7.8% growth in Innovative Medicine and 4.5% in MedTech. Management increased the midpoint of 2026 guidance by $300 million on the top line and $0.13 on the bottom line. Shares fell 2% intraday on July 15.

Sponsor Center